4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
Portfolio Pulse from Nabaparna Bhattacharya
Chardan Research analyst Geulah Livshits initiated coverage on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with a Buy rating and a price target of $30. The analyst is optimistic about the company's directed evolution of the Adeno-associated virus platform, or AAV, to tackle historical obstacles in vivo gene delivery. The company's pipeline, which includes three clinical-stage ophthalmology assets, is also praised. The analyst believes that discussions with the FDA on pivotal endpoints in 4Q should provide visibility on the path to market.
July 05, 2023 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics received a Buy rating and a price target of $30 from Chardan Research. The company's AAV platform and clinical-stage ophthalmology assets were highlighted positively. The stock is expected to perform well in the short term.
The positive coverage from Chardan Research, along with the Buy rating and a price target of $30, indicates a strong outlook for 4D Molecular Therapeutics. The company's AAV platform and clinical-stage ophthalmology assets are seen as strong points, which could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100